Treatment with ribavirin and interferon-α reduces interferon-γ expression in patients with chronic hepatitis C

Clinical and Experimental Immunology

Volumn 123, Issue 3, 2001, Pages 459-464

  Bergamini, A ^a   Bolacchi, F ^a   Cepparulo, M ^a   Demin, F ^a   Uccella, I ^a   Bongiovanni, B ^a   Ombres, D ^a   Angelico, F ^a   Liuti, A ^a   Hurtova, M ^a   Francioso, S ^a   Carvelli, C ^a   Cerasari, G ^a   Angelico, M ^a   Rocchi, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chronic hepatitis C; IFN ; IFN ; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; RIBAVIRIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LIVER INJURY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RIBAVIRIN; VIRAL LOAD;

EID: 0035073166     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01468.x     Document Type: Article

References (25)

1. Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in vivo
2. Antiviral activities of ribavirin, 5-ethynyl-l-beta-Dribofuranosyl-imidazole-4carboxamide, and 6′-(R)-6′-C-methylneoplanocin A against several ortho- and para-myxoviruses
3. A pilot study of ribavirin therapy for chronic hepatitis C
4. Ribavirin treatment for patients with chronic hepatitis C. Results of a placebo-controlled study
5. Ribavirin as therapy for chronic hepatitis C
6. Prolonged therapy of chronic hepatitis C with ribavirin
7. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C
8. Randomised trial of Interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus Interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
9. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C. HCV RNA at 4 weeks versus ALT
10. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a
11. Interferon-α-2b and ribavirin in combination for chronic hepatitis C patients not responding to Interferon-α alone: An italian multicenter, randomized, controlled, clinical study
12. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune response
13. Ribavirin polarizes human T cell responses toward a type 1 cytokine profile
14. Effects of the ribavirin-interferon a combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients
15. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines
16. Different cytokines profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infection
17. Detection of intracellular cytokines by flow cytometry
18. Interferons
19. The expanding universe of T cell subset: Th1, Th2 and more
20. The effects of IL-4 on human natural killer cells, α potent regulator of IL-2 activation and proliferation
21. IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells
22. Interferon-alpha treatment induces delayed CD4+ proliferative responses to the hepatitis C virus non-structural 3 protein regardless of the outcome of therapy
23. CD40 and CD154 in cell-mediated immunity
24. Human Th1 and Th2 cells: Functional properties, mechanisms of regulation, and role in diseases